Premium
Exogenous hormone use and fibrocystic breast disease by histopathologic component
Author(s) -
Berkowitz Gertrud S.,
Kelsey Jennifer L.,
Livolsi Virginia A.,
Merino Maria J.,
Holford Theodore R.,
Hildreth Nancy G.,
Ort Sharon,
O'Connor Theresa Z.,
White Colin
Publication year - 1984
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910340403
Subject(s) - medicine , papillomatosis , atypia , biopsy , fibrocystic breast disease , atypical hyperplasia , hyperplasia , estrogen , mammography , breast disease , gynecology , fibrocystic disease , pathology , breast cancer , cancer
In a hospital‐based case‐control study of 590 women with biopsy‐proven fibrocystic breast disease and 1,018 control women with other surgical conditions, no linear relationship was evident between the use of oral contraceptives or of estrogen replacement therapy and the degree of epithelial atypia of the fibrocystic lesions. Case‐control and intracase comparisons suggested that oral contraceptive use might be associated with an increased occurrence of sclerosing adenosis among the premenopausal women and of gross cysts among the postmenopausal women. Estrogen replacement therapy, which was positively associated with fibrocystic breast disease as a whole among the postmenopausal women, was most frequently used among the cases whose biopsy specimens exhibited gross cysts, papillomatosis or papillary hyperplasia.